AstraZeneca's Coronavirus Vaccine Candidate Posts Positive Results
Highly anticipated trial results for a coronavirus vaccine candidate AstraZeneca (NYSE: AZN) licensed from Oxford University reached The Lancet, a major medical journal, on Monday. And they put the adenovirus-based candidate, called AZD1222, firmly in the lead in the race to develop vaccines that can end the COVID-19 pandemic.
This was a big early-stage trial with 1,077 healthy patients randomized to receive a single injection of AZD1222 or a meningitis vaccine as a control. The investigators also gave 10 patients in the AZD1222 group a booster shot after 28 days.
Image source: Getty Images.
Source Fool.com
